1. Home
  2. GANX vs FTCI Comparison

GANX vs FTCI Comparison

Compare GANX & FTCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • FTCI
  • Stock Information
  • Founded
  • GANX 2017
  • FTCI 2017
  • Country
  • GANX United States
  • FTCI United States
  • Employees
  • GANX N/A
  • FTCI N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • FTCI Semiconductors
  • Sector
  • GANX Health Care
  • FTCI Technology
  • Exchange
  • GANX Nasdaq
  • FTCI Nasdaq
  • Market Cap
  • GANX 41.9M
  • FTCI 43.8M
  • IPO Year
  • GANX 2021
  • FTCI 2021
  • Fundamental
  • Price
  • GANX $2.27
  • FTCI $3.25
  • Analyst Decision
  • GANX Strong Buy
  • FTCI Buy
  • Analyst Count
  • GANX 5
  • FTCI 4
  • Target Price
  • GANX $7.60
  • FTCI $8.13
  • AVG Volume (30 Days)
  • GANX 218.6K
  • FTCI 97.9K
  • Earning Date
  • GANX 03-25-2025
  • FTCI 03-12-2025
  • Dividend Yield
  • GANX N/A
  • FTCI N/A
  • EPS Growth
  • GANX N/A
  • FTCI N/A
  • EPS
  • GANX N/A
  • FTCI N/A
  • Revenue
  • GANX N/A
  • FTCI $57,354,000.00
  • Revenue This Year
  • GANX N/A
  • FTCI N/A
  • Revenue Next Year
  • GANX N/A
  • FTCI $200.62
  • P/E Ratio
  • GANX N/A
  • FTCI N/A
  • Revenue Growth
  • GANX N/A
  • FTCI N/A
  • 52 Week Low
  • GANX $0.89
  • FTCI $1.76
  • 52 Week High
  • GANX $5.19
  • FTCI $7.40
  • Technical
  • Relative Strength Index (RSI)
  • GANX 47.71
  • FTCI 39.91
  • Support Level
  • GANX $2.30
  • FTCI $2.92
  • Resistance Level
  • GANX $2.81
  • FTCI $3.82
  • Average True Range (ATR)
  • GANX 0.25
  • FTCI 0.34
  • MACD
  • GANX -0.03
  • FTCI -0.00
  • Stochastic Oscillator
  • GANX 35.33
  • FTCI 25.78

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

About FTCI FTC Solar Inc.

FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.

Share on Social Networks: